Last updated: September 21, 2026
Triclabendazole is a specialized antiparasitic used primarily to treat fascioliasis caused by Fasciola hepatica and Fasciola gigantica. The U.S. market is small, concentrated and procurement-driven rather than prescription-commercial. Novartis’ Egaten 250 mg tablet is the principal branded product and has been supplied through public-health programs and donation channels. Public revenue attributable to triclabendazole is not separately disclosed.
The commercial outlook depends on three factors: the global burden of fascioliasis, government and nongovernmental procurement, and the availability of quality-assured generic or locally manufactured products. Patent protection is not the main barrier to entry. Regulatory approval, manufacturing capability, supply reliability and access to public tenders are more important.
What is triclabendazole used for?
Triclabendazole is a benzimidazole anthelmintic with activity against immature and adult liver flukes. It is the preferred treatment for human fascioliasis because it is effective against parasite stages that are not reliably treated by older anthelmintics.
| Attribute |
Publicly documented position |
| Active ingredient |
Triclabendazole |
| Primary indication |
Fascioliasis |
| Main pathogens |
Fasciola hepatica and Fasciola gigantica |
| U.S. dosage form |
250 mg oral tablet |
| U.S. administration |
Two doses given 12 hours apart with food |
| U.S. approved product |
Egaten |
| U.S. sponsor |
Novartis Pharmaceuticals Corporation |
| FDA approval |
February 28, 2019 |
| Main buyers |
Hospitals, governments, ministries of health and public-health agencies |
| Market structure |
Niche, concentrated and procurement-led |
The World Health Organization recommends triclabendazole for human fascioliasis and has identified the disease as a neglected tropical disease. Treatment demand is concentrated in endemic areas of Latin America, Africa, the Middle East and parts of Asia (World Health Organization, 2023).
How large is the triclabendazole market?
The global triclabendazole market does not have a reliable, publicly reported revenue figure. Major pharmaceutical companies generally do not report Egaten revenue as a standalone product. Commercial market-research estimates vary because they often combine human treatment, veterinary products, regional distributors and public-sector donations.
The addressable human market is constrained by the disease population rather than by broad primary-care prescribing. Fascioliasis is endemic in farming and livestock-producing regions, but diagnosis is uneven and many cases are managed through public-health campaigns. The drug is also used in outbreak response and targeted treatment programs rather than continuous chronic therapy.
Demand drivers
The principal demand drivers are:
- WHO and national treatment programs in endemic countries.
- Diagnosis of fascioliasis in migrant, agricultural and rural populations.
- Hospital demand for imported cases in the United States and Europe.
- Veterinary disease control, which supports manufacturing familiarity but is separate from the human regulatory market.
- Public procurement following local outbreaks or epidemiologic surveys.
- Expansion of neglected-disease financing and donor-supported medicine access.
Demand constraints
Demand is limited by:
- The relatively small diagnosed patient population.
- Underdiagnosis and limited laboratory capacity.
- Low treatment frequency per patient.
- Public-sector price sensitivity.
- Competition from veterinary channels in manufacturing and distribution.
- Supply-chain dependence on a small number of qualified producers.
A financial model based on mass-market pharmaceutical assumptions would overstate the opportunity. Triclabendazole is a high-importance medicine in a narrow therapeutic category, but it is not a large commercial franchise.
What is the financial trajectory for triclabendazole?
The financial trajectory is more likely to show stable, low-volume institutional demand than rapid commercial growth. Public revenue disclosure is insufficient to establish a precise historical sales curve.
| Period |
Market development |
Financial implication |
| Before 2019 |
Triclabendazole was used internationally, including through WHO and public-health channels, but lacked a U.S. FDA-approved human product |
Limited U.S. commercial opportunity |
| 2019 |
FDA approved Egaten for fascioliasis |
Created a formal U.S. product and reimbursement pathway |
| 2020-2022 |
Pandemic disruption affected diagnosis, hospital activity and procurement in many neglected diseases |
Potential short-term demand volatility |
| 2023-2024 |
Continued use in endemic-country programs and specialist U.S. treatment |
Stable niche demand; no evidence of mass-market expansion |
| Longer term |
Growth depends on diagnosis, donor procurement and generic quality assurance |
Moderate unit growth possible, limited revenue scale |
Novartis has historically supplied Egaten through donation and access programs, including arrangements connected to the WHO. Donation volumes and program economics are not equivalent to conventional branded sales and should not be used to infer net commercial revenue (Novartis, 2023; World Health Organization, 2023).
The most realistic commercial scenarios are:
- A stable branded-plus-public-procurement market with limited revenue growth.
- Gradual generic erosion if additional human products obtain regulatory approval.
- Periodic demand spikes caused by outbreaks, tenders or expanded screening.
- Regional substitution by quality-assured manufacturers in endemic countries.
What is the FDA regulatory status of triclabendazole?
The FDA approved Egaten on February 28, 2019, under New Drug Application 212269 for the treatment of fascioliasis in patients aged 6 years and older weighing at least 30 kilograms. The product is administered orally as two 250 mg doses taken 12 hours apart with food.
The FDA approval was important because triclabendazole had long-standing international use but lacked a U.S.-approved human product. The approval established a reference product for U.S. regulatory purposes and enabled formal prescribing, labeling and adverse-event monitoring.
The product label identifies common adverse reactions including abdominal pain, nausea, headache and elevated liver enzymes. The label also addresses QT prolongation and drug interaction considerations (U.S. Food and Drug Administration, 2019).
What is the Orange Book status of triclabendazole?
Egaten is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, as the reference-listed drug for triclabendazole tablets. Public Orange Book data should be checked by product and update date because listing status, marketing status and patent information can change.
The commercially relevant point is that the product’s market position does not appear to rest on a substantial publicly identified patent thicket. Regulatory approval, supply reliability and procurement access are more material barriers than Orange Book patent exclusivity.
What patents protect triclabendazole?
Triclabendazole itself is an old active pharmaceutical ingredient. The molecule and its core anthelmintic use are outside the normal period of composition-of-matter protection for a modern branded medicine.
Publicly available U.S. product information does not indicate a significant active-patent estate surrounding the basic triclabendazole molecule. The principal protection issues are more likely to involve:
- Manufacturing processes.
- Crystalline or solid-state forms.
- Tablet composition and excipients.
- Dissolution or bioavailability improvements.
- Packaging and stability.
- Specific dosing regimens.
- Veterinary formulations.
These categories do not automatically create enforceable barriers against a conventional human 250 mg tablet. A generic applicant could face process or formulation claims, but the commercial impact depends on claim scope, validity and design-around options.
How strong is the patent estate for triclabendazole?
The patent estate appears weak relative to newer small-molecule drugs. The reasons are structural:
- The active ingredient is old.
- The main indication is established.
- The dosing regimen is conventional.
- The FDA-approved formulation is an oral tablet.
- The market is too small to support extensive patent litigation in most scenarios.
Any later-filed formulation or method-of-use patent would need to overcome prior-art and obviousness risks. A patent directed to a narrow dosing population could remain relevant to labeling, but it would not necessarily block an unclaimed use.
When does triclabendazole lose exclusivity?
Triclabendazole’s core molecular exclusivity expired long before the FDA approval of Egaten. The key U.S. commercial protection associated with the 2019 approval was regulatory exclusivity, not new-molecule patent protection.
The FDA approval of an old drug does not automatically create five years of new chemical entity exclusivity. The applicable exclusivity period depends on the statutory basis of approval and the clinical-investigation data supporting the application. Public sources do not establish a material, long-duration exclusivity period that would block all competing triclabendazole products.
The practical conclusion is that generic entry risk is present once a competing manufacturer has an approvable human product. The absence of a large patent estate reduces the likelihood that litigation will delay entry for many years.
Are there Paragraph IV challenges or triclabendazole patent lawsuits?
No major publicly reported U.S. Paragraph IV litigation or settlement involving Egaten had emerged in the public record through June 2024. That is consistent with the product’s small market, limited apparent patent coverage and low expected litigation value.
A future abbreviated new drug application could challenge any listed patent by Paragraph IV certification. The expected litigation risk would depend on whether the Orange Book contains active patents covering the product, formulation or method of use at the time of filing.
What generic launch risks exist?
A generic entrant would face more operational than patent-related risks:
- Demonstrating pharmaceutical equivalence to the reference tablet.
- Establishing bioavailability or a justified biowaiver pathway.
- Securing active-ingredient supply.
- Meeting FDA current good manufacturing practice requirements.
- Obtaining procurement contracts.
- Maintaining stock for sporadic demand.
- Competing against donated or subsidized branded supply.
A low-price generic may not achieve attractive returns unless it wins public tenders or sells into several jurisdictions. Market entry could therefore occur without producing meaningful price erosion if the entrant lacks distribution scale.
What formulations are protected by triclabendazole patents?
The principal human formulation is a 250 mg immediate-release tablet. No publicly established, commercially dominant patented delivery system is associated with the product.
Potential development opportunities include:
- Pediatric lower-strength tablets.
- Dispersible or liquid formulations.
- Improved taste-masked products.
- Fixed-dose or combination antiparasitic products.
- Formulations designed for patients with swallowing difficulties.
- Packaging optimized for public-health distribution.
These opportunities have limited commercial value unless they solve a documented access problem. Pediatric use is particularly relevant because the U.S. label covers patients aged 6 years and older who meet the weight threshold, while endemic-country programs may treat different age groups under local protocols.
Is there biosimilar risk for triclabendazole?
Biosimilar risk is not relevant. Triclabendazole is a chemically synthesized small molecule, not a biologic. Competing products would generally use generic-drug pathways, national registration procedures or other small-molecule approval routes.
The competitive risk is therefore generic substitution, not biosimilar interchangeability.
Which companies are challenging the triclabendazole market?
The market is not characterized by a clearly disclosed group of large branded challengers. Potential competitors include:
- Generic pharmaceutical manufacturers in India, China and Latin America.
- Regional producers supplying endemic-country tenders.
- Veterinary pharmaceutical companies with triclabendazole manufacturing expertise.
- Contract manufacturers producing active ingredient or finished tablets.
- Public-sector manufacturers and nonprofit supply organizations.
Many manufacturers may produce veterinary triclabendazole without holding approval for a human product. Veterinary availability should not be treated as evidence of FDA-approved human competition.
How does triclabendazole compare with competing antiparasitic drugs?
Triclabendazole has a differentiated position because few widely used anthelmintics reliably treat both immature and adult Fasciola parasites.
| Drug |
Principal role in fascioliasis |
Competitive position |
| Triclabendazole |
Preferred treatment for human fascioliasis |
Direct therapeutic benchmark |
| Praziquantel |
Used for several trematode infections, but not the preferred treatment for fascioliasis |
Limited substitution |
| Albendazole |
Broad-spectrum anthelmintic |
Not an equivalent substitute for fascioliasis |
| Mebendazole |
Broad-spectrum anthelmintic |
Limited relevance |
| Bithionol |
Historical fascioliasis treatment |
Older and less favored option |
| Nitazoxanide |
Investigational or limited alternative use in some settings |
Not a standard replacement |
The limited number of clinically credible substitutes supports continued demand even if generic versions reduce price.
What licensing deals and access arrangements affect triclabendazole?
The most important access arrangement has been Novartis’ long-running donation and public-health support for Egaten. WHO materials have described donation programs supporting treatment of fascioliasis in endemic countries. These arrangements expand patient access but can reduce conventional commercial revenue and complicate market-size calculations.
The commercial effects are mixed:
- Donation programs increase treatment volumes.
- Public procurement can create predictable institutional demand.
- Subsidized supply can reduce the price ceiling for commercial entrants.
- Manufacturers may avoid markets where donation supply is sufficient.
- Governments may prefer quality-assured donated product during outbreaks.
No major recent licensing transaction has established a high-value commercial platform around triclabendazole.
What manufacturing and geographic barriers affect entry?
Manufacturing access is a more credible barrier than composition-of-matter patent protection. Entrants need qualified active pharmaceutical ingredient, validated tablet production, stability data and regulatory documentation.
Geographic considerations are material:
- The United States requires FDA-compliant manufacturing and an approved application.
- The European Union requires authorization under the applicable national or centralized pathway.
- Endemic countries may rely on WHO prequalification, national registration or tender-specific requirements.
- Latin American and African markets can be fragmented across ministries, hospitals and distributors.
- Public tenders often reward low price, supply continuity and prior performance.
A supplier with only a manufacturing license but no human regulatory approval cannot directly compete with Egaten in regulated human markets.
What is the likely generic launch scenario?
The most likely generic-entry path is regional rather than a large U.S. launch. A manufacturer could first target countries with significant fascioliasis prevalence, established public tenders and less costly registration requirements. U.S. entry would require a viable commercial rationale despite the small patient population.
Potential outcomes include:
| Scenario |
Probability profile |
Market effect |
| No meaningful new entrant |
Plausible if returns remain low |
Egaten retains institutional position |
| Regional generic entry |
Most commercially logical |
Price pressure in selected endemic markets |
| U.S. generic approval |
Possible but economically difficult |
Greater procurement leverage and lower U.S. price |
| Multiple global entrants |
Less likely without donor or tender expansion |
Significant price erosion |
| New pediatric formulation |
Technically feasible |
Access improvement, limited revenue expansion |
What is the investment and licensing outlook?
Triclabendazole is more attractive as a public-health supply opportunity than as a conventional branded pharmaceutical investment. The strongest assets are likely to be:
- Reliable API sourcing.
- Low-cost, quality-assured tablet production.
- Regulatory approvals in endemic countries.
- Access to government tenders.
- Pediatric or dispersible formulations.
- Distribution relationships with ministries of health and international agencies.
The weakest investment thesis is a patent-led strategy. The active ingredient is old, the apparent patent estate is limited and the market does not support large litigation budgets. A buyer valuing the product should focus on tender history, donation dependence, gross-to-net pricing, manufacturing cost and geographic registrations rather than patent term.
Key Takeaways
- Triclabendazole is a niche antiparasitic with high clinical importance in fascioliasis and limited commercial scale.
- Egaten is the principal U.S. reference product and was FDA approved in 2019.
- Public revenue for triclabendazole is not separately disclosed.
- Demand is driven by government procurement, public-health programs and imported-case treatment.
- The core molecule is old, and no substantial publicly identified U.S. patent barrier appears to protect the basic product.
- Paragraph IV litigation and major patent settlements were not publicly evident through June 2024.
- Generic entry risk is real, but manufacturing, registration and tender access are more important than patent litigation.
- Biosimilar competition does not apply because triclabendazole is a small-molecule drug.
- Novartis donation and access programs support patient volume while limiting conventional commercial pricing.
- The most credible growth opportunities are regional supply, quality-assured generics and pediatric or dispersible formulations.
FAQs
Is triclabendazole available over the counter?
No. Human use generally requires a prescription or distribution through an authorized public-health or hospital program. Veterinary products should not be treated as approved human substitutes.
Is Egaten still the only FDA-approved human triclabendazole product?
Public FDA product information identifies Egaten as the established FDA-approved human product. Generic approvals and marketing status should be confirmed against the current FDA Orange Book before making a procurement or litigation decision.
Can triclabendazole treat schistosomiasis?
No. Triclabendazole is directed primarily at fascioliasis. Praziquantel is the standard treatment for many schistosomiasis infections.
Is triclabendazole resistant to patent challenges?
The old age of the active ingredient reduces composition-of-matter patent risk, but a particular formulation or manufacturing patent could still be challenged on validity, scope or infringement grounds.
What would most increase triclabendazole sales?
Expanded diagnosis and treatment of fascioliasis, sustained donor procurement, new national registrations and reliable pediatric formulations would have a greater effect on sales than additional branded promotion.
References
-
Novartis. (2023). Annual report 2023. Novartis AG.
-
U.S. Food and Drug Administration. (2019). Egaten (triclabendazole) tablets, prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: Egaten, NDA 212269. FDA.
-
World Health Organization. (2023). WHO guideline for the control and elimination of human fascioliasis. WHO.
-
World Health Organization. (2023). WHO model list of essential medicines, 23rd list. WHO.
